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In the current study we tested if highest incidence of benign as well as cancer growths in breast tis-
sue is due to constitutive molecular composition of this tissue. To delineate the molecular basis, we
compared the expression of nine functional gene modules (total 578 genes) that regulate major
positive growth and negative inhibitory signals in normal breast with two other reproductive tis-
sues, ovary and uterus. We present data to demonstrate that breast tissues constitutively have very
highly elevated levels of several growth promoting molecules and diminished levels of inhibitory
molecules which may, in part, contribute for highest incidence of tumor growths in this tissue.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Numerous surveys have established that the incidence of
benign as well as malignant growths is highest in breast among
all male and female reproductive and non-reproductive tissues.
Surveys show that in the USA alone, about 1–1.5 million benign
and 180 000–200 000 cancer cases of the breast are reported per
year and breast cancers account to a third of all male and female
cancers combined [1–3]. Based on experimental, clinical and epi-
demiological studies it is widely believed that estrogen promotes
benign as well as malignant growths in breast tissues. Although
estrogens are known to mediate a wide variety of complex
seemingly unlinked biological processes in a diverse range of
reproductive and non-reproductive tissues, it is not known why
mitogenic actions of estrogens are implicated as a cause of devel-
oping benign as well as malignant growths only in breast but not
other target tissues. Interestingly, the incidence of benign and
malignant growths in ovary and uterus, the primary sites ofchemical Societies. Published by E
Surgery, Howard University
DC 20059, United States. Fax:estrogen production and action, respectively, are substantially
lower than breast. Although estrogens are also implicated in pro-
moting the ovarian and uterine cancers, anti-estrogen treatments
have little beneﬁt to these patients.
It is largely not known why tumor growths are highest in breast
and why estrogen promotes the genesis and progression of cancers
only in breast but not other target tissues. To delineate the molec-
ular bases for the above, we compared the expression of nine func-
tional gene modules (a total of 578 genes), which regulate major
positive growth and negative inhibitory signals, in normal breast
with normal ovary and uterus tissues. They were: (1) growth fac-
tors, growth factor binding proteins and growth factor receptors
(n = 177), (2) steroid receptor co-activators (n = 20), (3) steroid
receptor co-repressors (n = 10), (4) kinases (n = 54), (5) tumor sup-
pressors (n = 30), (6) oncogenes (n = 124), (7) apoptosis regulators
(n = 71), (8) genes that regulate estrogen metabolism (n = 88), and
(9) hormone receptors (n = 4). We selected the above functional
gene modules because altered expressions of these are known to
directly or indirectly support or suppress tumor growths.
We present results here to demonstrate for the ﬁrst time that
breast tissue constitutively has highly elevated levels of several
molecules that promote cell proliferation, survival and angiogene-
sis which are either absent or at far diminished levels in otherlsevier B.V. All rights reserved.
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els of negative signaling molecules that inhibit proliferation and
promote apoptosis, differentiation, and tumor suppression in com-
parison with other reproductive tissues. The molecular constitu-
tion of breast tissue may, in part, contribute for highest incidence
of tumor growths in this tissue.2. Materials and methods
ABC staining system and primary antibodies against EGFR,
EGFL6, ERa, and LTBP1 were from Santa Cruz Biotechnologies.
Anti-NCOA4 antibodies were from Abnova Corp. Taiwan. Labeled
Envision+ polymer-HRP and DAB were from Dakocytomation.
The Taqman Gene Expression Assay reagents were obtained from
Applied Biosystems. The ID# for EGFL6, EGFR, TUSC3, NCOA4, FGF-
1, LTBP1 and GHR were Hs00170955_m1, Hs00193306_m1, Hs00
394808_m1, Hs00428328_m1, Hs00265254_m1, Hs00386448_m1
and Hs00174872_m1, respectively.
2.1. Tissue samples
Normal breast tissues were obtained from women undergoing
reduction mammoplasty for cosmetic reasons with no prior history
of breast cancer. Normal ovary and uterus tissues were also ob-
tained from women undergoing surgery for non-cancerous condi-
tions and the absence of any abnormal cells in the collected
tissues was veriﬁed by histological staining. All the tissues were
collected from Howard University Hospital Surgical Pathology,
immediately after surgery and stored at 80 C until use. Formalin
ﬁxed parafﬁn embedded normal breast (reduction mammoplasty),
ovary and uterus tissues were obtained from Howard University
pathology tissue archives. The samples were from both premeno-
pausal and post-menopausal women.
2.2. Micro-array analyses and real-time Q PCR
RNA extraction, puriﬁcation and cDNA preparations were per-
formed as previously described [4,5]. Gene expression analysis by
micro-arrays was performed on U133A Human GeneChip (Affyme-
trix) that represents 22 283 biological oligonucleotides including
normalization controls as previously described [6]. A total of three
runs were performed for each of normal ovary, breast and uterus
tissue samples. Each sample for micro-array analysis was prepared
by pooling equal amounts of four different individual tissue RNA
samples. Quantitative real-time PCRs were performed in ABI Prism
GeneAmp 7900HT Sequence Detection System at a modiﬁed 50%
Ramp rate as previously described [6–8] using gene speciﬁc as-
says-on-demand reagents from Applied Bio-Systems. All the sam-
ples were ampliﬁed in triplicate and real-time PCRs were
repeated four times and normalized to the copy numbers of the
housekeeping gene, GAPDH. Absolute quantiﬁcations of GAPDH,
wild type ERa, wild type ERb, various isoforms of ERa and ERb
mRNA copy numbers by RT real-time Q PCR were performed as
previously described [7,8].
2.3. Immunohistochemical staining
Expression of selected number of genes was studied at protein
levels by Immunohistochemistry (IHC) using the previously estab-
lished procedures [5,6,9,10]. Brieﬂy, the slides were deparafﬁnized,
antigens retrieved in 10mM citrate buffer by heating for 25 min in
a steamer and endogenous peroxides blocked by incubating with
3% H2O2 in methanol for 20 min as previously described [9,10].
The slides were blocked with blocking solution and incubated with
primary antibodies for 90 min. The blocking buffer for LTBP1,EGFL6, and EGFR was 1% BSA, 0.1% Fish Gelatin, 0.1% Triton X-
100 and 0.05% Tween 20 in 1  PBS and for NCOA4 and ERa the
above solution without ﬁsh gelatin. The primary antibody dilutions
for LTBP1, EGFL6, ERa, EGFR and NCOA4 were 1:200, 1:200, 1:100,
1:50, and 1:100, respectively. The EGFL6 and LTBP1 antibodies
were diluted in 1.5% donkey serum in PBS. The EGFR, ERa and
NCOA4 antibodies were diluted in PBS. The secondary antibodies
for EGFL6 and LTBP1 were goat–ABC staining system. For EGFR it
was anti-rabbit labeled Envision+ polymer-HRP. For NCOA4 and
ERa they were anti-mouse labeled Envision+ polymer-HRP. The
peroxidase substrate for all was DAB (DakoCytomation, #K3468).
All the stained slides were scored independently by two patholo-
gists for staining intensity and scored using an arbitrary scale of
0–3, 3 being the slide with the highest staining intensity and score
0 for slides with no stain.
2.4. Statistical analyses
The expression of 9 functional gene modules (a total of 578
genes, Supplementary Table 1) in breast tissue was compared with
ovary and uterus tissues. In order to identify genes that were differ-
entially expressed in breast tissue in comparison with ovary and
uterus tissue, logarithmic ratios (to the base 2) of breast/ovary
and uterus were calculated by comparison analysis using GCOS
for all 18 combinations of breast and ovary and uterus pairs. Mean
of all ratios, one sample t-test P-value, number of Increase, and De-
crease calls were calculated for each gene. Differentially expressed
genes in breast tissue were selected in comparison with ovary and
uterus tissues based on: (1) the qualities of the 18 ratios, (2) the
t-test P-values from the 18 ratios, (3) themean of all 18 signal ratios
and (4) the numbers of Increase and Decrease calls. The four condi-
tions were set as in the following. To control the quality of the ra-
tios, at least 10 out of the 18 ratios must satisfy one of the three
conditions: a ‘‘change” P-value <0.003 (Increase) or >0.997 (De-
crease) or a signal detection P-value <0.065. The t-test P-value
was less than 0.001. The mean of all 18 signal ratios (change fold)
was at least 1.5 and the numbers of Increase and Decrease calls
were not the same. Statistical analyses of RT real-time Q PCR and
IHC data were performed usingWilcoxon test and one way ANOVA.
The results were considered signiﬁcant if the P-values were <0.05.3. Results
To delineate the molecular bases for highest incidence of tumor
growths in breast tissue, we ﬁrst performed global gene expression
of normal female human breast tissue and two other normal repro-
ductive tissues, ovary and uterus, the primary sites of estrogen
synthesis and action, respectively. We next compared the expres-
sion levels of nine functional gene modules which regulate major
positive growth and negative inhibitory signals, in breast with
ovary and uterus. They were: (1) growth factors, growth factor
binding proteins and growth factor receptors (n = 177), (2) steroid
receptor co-activators (n = 20), (3) steroid receptor co-repressors
(n = 10), (4) kinases (n = 54), (5) tumor suppressors (n = 30), (6)
oncogenes (n = 124), (7) apoptosis regulators (n = 71), (8) genes
that regulate estrogen metabolism (n = 88), and (9) hormone
receptors (n = 4) (Supplementary Table 1).
3.1. Breast tissue had similar expression levels of over 90% of genes
compared with ovary and uterus
At the statistical signiﬁcance level speciﬁed in methods, of the
578 genes compared all but 53 showed surprisingly similar
expression levels in all three tissues. Of the 53 differentially ex-
pressed genes, 25 were over-expressed and 28 were under-
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mentary Table 2). The functional categories of the differentially ex-
pressed genes are given in Table 1.
3.2. Breast tissue was constitutively rich with a number of growth
promoting positive signaling molecules – genes that inhibit apoptosis
and promote cell proliferation, survival, and angiogenesis
Three growth factors, EGF, EGFL6 and IGF-1, which require
estrogen for their actions and stimulate cell cycle progression by
activating ras-raf-MAPK1-erk cascade, activating PI3K/AKT sur-
vival pathways and various transcription factors such as c-fos,
c-jun, c-myc, STATS and inactivating apoptosis inducers, are abun-
dantly expressed in breast tissues. EGFR that regulates multiple
biological processes such as proliferation, angiogenesis, inhibition
of apoptosis, and promote tumor cell motility, adhesion, invasion
and metastasis was expressed in large amounts only in breast tis-
sue in addition to abundant amounts of its ligands. EGFR protein
was totally absent in ovary and uterus tissues (Fig. 2A, lower pa-
nel). MET oncogene that has receptor tyrosine kinase activity and
other functional properties similar to EGFR was also at elevated
levels in breast tissue. To complement higher expression levels of
EGFL6, IGF, EGF, EGFR and MET, higher levels of signal transmitter
adaptor family members, CRK and VAV3, were at elevated levels in
breast. Breast tissues also constitutively had abundant levels of
growth factors, VEGF-B, VEGF-D, ECGF-1, FGF-1 and FGF-2, some
of which correlate to estrogen levels [11] and are known to pro-
mote angiogenesis by stimulating endothelial cell proliferation,
adhesion, migration, invasion and morphogenesis. The expressions
of the above growth factors were either absent or at markedly
diminished levels in ovary and uterus.
To complement the signals transmitted by the above growth
factors, breast tissues also had higher expression levels of kinases
required for nucleic acid synthesis (UMP-CMPK), assembly of com-
ponents of the transcription machinery (HIPK2) and translation
initiation (MKNK2). In addition, expression of cell survival pro-
moter (SGKL) and apoptosis inhibitor (CFLAR) were also at elevated
levels in this tissue. Unexpectedly, GHR that is required for breast
development and functionally linked to IGF production was the
most highly over-expressed among the differentially expressed
genes in breast. GHR was at markedly at far diminished levels in
ovary and uterus (Fig. 1 and Supplementary Table 2).
3.3. Breast tissue was constitutively very poor in negative signaling
molecules – genes that promote differentiation and apoptosis and
suppress proliferation
Two IGF binding proteins, IGFBP4 and IGFBP5, which limit the
availability of IGF and independently inhibit DNA synthesis, arrest
cell cycle progression and promote differentiation, were poorlyTable 1
Functional categories of genes signiﬁcantly over-, and under-expressed in breast in compa
# Functional category Genes signiﬁcantly ove
1. Growth factor mediated signaling (growth factors,
growth factor binding proteins and growth factor
receptors)
EGF, EGFL6, EGFR, FGF-
1, VEGF-B, FIGF (VEGF-
TGFBR3
2. Oncogenes VAV3, RAB7L1, CRK, RA
3. Tumor suppressors FAT
4. Steroid receptor co-activators NCOA4
5. Steroid receptor co-repressors None
6. Kinases MKNK2, SGKL, PGK1, H
7. Apoptosis CFLAR, CASP1
8. Hormone receptors GHR
9. Genes involved in estrogen metabolism Noneexpressed in breast tissue. Three TGFb binding proteins, LTBP1,
LTBP3 and LTBP4, known to be required for the storage, activation
and targeting of TGFb to its cell surface receptor were under-
expressed in breast. Under-expression of one of the above pro-
teins, LTBP1, in breast tissue at the mRNA levels could be seen
in Fig. 1 and at protein levels in representative tissues by IHC in
Fig. 2B (lower panel). Diminished levels of the above binding
proteins could limit the availability of proliferation inhibiting
and differentiation and apoptosis promoting TGFb levels in breast
tissue. Other growth factors expressed at lower levels in breast
were involved in either promoting differentiation (FGF-9, EBAF,
PSIPI, CTGF, PDGFC, PDGFRA) or coordinating intercellular com-
munications (CTGF). The JUN-D proto-oncogene, which was
known to reduce cell proliferation, inhibit angiogenesis and pro-
mote differentiation, was lowest in breast. Two other differentia-
tion promoting proto-oncogenes, MAFF-1 and FOSB-1 were also at
lower levels. Four tumor suppressors, GLTSCR2, TUSC3, WT1, and
TSC22, were expressed at signiﬁcantly diminished levels in breast.
In addition to lower levels of differentiation promoting molecules,
breast tissue had under-expression of genes involved in inducing
apoptosis (CASP9), nuclear transport of proteins necessary for
apoptosis (CSEIL), and transcription of genes required for apopto-
sis response (DPF2).
3.4. Breast tissue was not signiﬁcantly different from ovary and uterus
in the levels of genes that regulate estrogen metabolism or signal
transmitting molecules
Interestingly, we did not observe any differences in the expres-
sions of 88 genes involved in estrogen metabolism or signaling in
breast. The level of ERa, the major player in mediating estrogen
signaling, was not signiﬁcantly different under the statistical crite-
ria applied. However, higher relative levels of several ER isoforms
(Supplementary Fig. 1A) were observed in breast tissues. Neither
ERb nor progesterone receptor were differentially expressed.
Interestingly ERa protein staining was observed in about 10% of
ductal epithelial cells of the breast and predominantly in the
nucleus where it is active in contrast to predominantly inactive
cytosolic staining in ovary and uterus cells (Supplementary
Fig. 1B). Of the several steroid receptor co-activators and co-
repressors, only NCOA4 that increases the activity of ERa and
other steroid/nuclear receptors was at highly elevated levels in
the breast tissue (Fig. 2B, upper panel). The staining pattern of
NCOA4 complemented ERa in that it is present predominantly in
nucleus where it is active in breast cells in contrast to predomi-
nantly cytosolic staining where it is inactive in ovary and uterus
cells. Other than ERa and NCOA4 nuclear localization, breast tissue
did not appear to be signiﬁcantly different in the levels of other
molecules involved in estrogen synthesis, metabolism or classical
estrogen signaling pathways.rison with ovary and uterus.
r-expressed Genes signiﬁcantly under-expressed
1(acidic), FGF-2, IGF-
D), ECGF-1, and
LTBP1, LTBP3, LTBP4, IGFBP4, IGFBP5, PDGFC, HDGFRP3,
FGF9, FGF-2R, EBAF (TGFbeta4), PDGFRA, PSIP1 and
CTGF
B5C, and MET MAFF, RAB31, JUN-D, RAB23, JUN and FOSB
GLTSCR2, TUSC3, WT1 and TSC22
None
None




Fig. 1. The expression of GHR, FGF-1, EGFL6, TUSC3 and LTBP1 in breast is distinct from other reproductive tissues. To corroborate the micro-array data, the expressions of
three over-expressed genes (GHR, FGF-1 and EGFL6) and two under-expressed genes (LTBP1 and TUSC3) were determined by RT Q real-time PCR using Taqman gene speciﬁc
assays-on-demand reagents from Applied Biosystems in individual cDNAs from 12 normal ovary, 22 normal uterus and 20 reduction mammoplasty tissues as described in
Section 2. The signal values of the above ﬁve genes normalized to GAPDH by micro-array analyses and RT Q real-time PCR are shown schematically. Heights of the boxes and
bars represent mean and standard deviations, respectively.
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diminished expression of TUSC3 and LTBP1 in breast tissue by micro-
array analyses could be independently veriﬁed by Q real-time PCR and
or immunohistochemistry (IHC)
To verify the micro-array data, three over-expressed genes,
GHR, FGF-1, EGFL6 and two under-expressed genes, TUSC3 and
LTBP1, were examined in a total of 22 normal uterus, 20 normal
breast (reduction mammoplasty) and 12 normal ovary tissues by
RT real-time QPCR using gene speciﬁc assays-on-demand reagents
from Applied Bio-systems and normalized to the copy numbers of
the house keeping gene, GAPDH. Analyses of the Q real-time PCR
data by Wilcoxon test conﬁrmed that the expression of the above
genes was signiﬁcantly different in breast in comparison with
ovary and uterus (P-values for the above markers were 0.00,
5.4e011, 2.4e6, 0.0054 and 7e6, respectively) and in concor-
dance with micro-array data (shown schematically in Fig. 1).
The micro-array data were further validated by IHC for three
over-expressed genes, EGFL6, EGFR, and NCOA4 and one under-ex-
pressed gene, LTBP1 (Table 1), in formalin ﬁxed parafﬁn embedded
archival normal ovary (n = 30), normal uterus (n = 27) and reduc-
tion mammoplasty tissues (n = 29) using their speciﬁc antibodies.
The staining grades of each of the above markers in breast were
compared with ovary and uterus by Wilcoxon test. We found the
above marker expressions at protein levels were consistently dif-
ferent in breast in comparison with ovary and uterus (P-values
5.9e7, 1e8, 1.2e5 and 2.2e14, respectively, for the above
markers) as observed by micro-array analyses establishing an
excellent concordance between mRNA and protein levels. IHC
staining of EGFL6 and EGFR in representative tissues is shown in
Fig. 2A and NCOA4 and LTBP1 in Fig. 2B. Although EGFR mRNA
was detected in ovary and uterus (Supplementary Tables 1 and
2), we could detect its protein only in breast but none in ovaryand uterus (Fig. 2A, lower panel). We also detected EGFL6 protein
only in breast (Fig. 2A, upper panel) as observed at mRNA levels
(Fig. 1 and Supplementary Tables 1 and 2). We observed heavy
NCOA4 protein staining in both nucleus and cytosol of breast cells,
but signiﬁcantly lower in ovary and uterus cells (Fig. 2B, upper pa-
nel). LTBP1 protein was abundantly expressed in ovary and uterus
but was signiﬁcantly lower in breast (Fig. 2B, lower panel) conﬁrm-
ing micro-array data. We also evaluated an association between
menopausal status and expression of the above proteins in all
the three tissues by ANOVA and did not ﬁnd any correlation.4. Discussion
In the current study we have addressed a fundamental question
of why of all human tissues breast is so highly prone to developing
tumor growths and of all target reproductive tissues, estrogen is
known to drive the tumor growths only in this tissue. We have
tested whether the molecular constitution of breast but not other
reproductive tissues is conducive to foster estrogen dependent tu-
mor growths. For our study, we selected ovary and uterus tissues
for comparative purpose because these tissues are the primary
sites of estrogen synthesis and action, respectively. In addition,
the incidences of malignant growths in the above tissues are far
(about 10- and 5-fold, respectively) lower than breast.
We studied the expression of nine functional gene modules that
regulate major positive growth and negative inhibitory signals and
could directly or indirectly drive or suppress tumor growths. The
results presented here show that breast tissue is surprisingly not
very different from ovary and uterus in the levels of molecules that
regulate estrogen metabolism or signaling. The only molecule
which showed signiﬁcant difference was NCOA4 that could in-
crease the transcription of genes under steroid hormone control
Fig. 2. EGFL6 and EGFR proteins were detected only in breast but not in ovary or uterus and NCOA4 and LTBP1 proteins were differentially expressed. The micro-array data
were further validated by immunohistochemistry for three over-expressed genes, EGFL6, EGFR, and NCOA4 and one under-expressed gene, LTBP1, in formalin ﬁxed parafﬁn
embedded archival normal ovary (n = 30), normal uterus (n = 27) and reduction mammoplasty tissues (n = 29) using their speciﬁc antibodies as described in Section 2.
Representative tissues for the above markers are shown. EGFR and EGFL6 proteins were totally absent in ovary and uterus (2A). NCOA4 and LTBP1 were differentially
expressed (2B).
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Fig. 3. Molecular pathway analysis using the Pathway Studio 6.2 program. The differentially expressed gene list (53 entities) (Supplementary Table 2) was imported into the
Pathway Studio program. Using the pathways/groups enriched analysis method, the above Cancer Pathways involving 33 entities was on the top of the list with P-value of
2.41  1031 are shown.
3074 I. Poola et al. / FEBS Letters 583 (2009) 3069–3075by interacting with estrogen receptor and several other steroid
receptors. Interestingly, the staining of NCOA4 was predominantly
in nucleus in the breast cells where it is active in contrast to pre-
dominantly cytosolic staining where it is inactive in ovary and
uterus cells (Fig. 2B, upper panel). ERa staining pattern comple-
mented NCOA4 in breast tissue in that it is predominantly in the
nucleus where as in ovary and uterus it was mostly in inactive
form in the cytosol (Supplementary Fig. 1B). The nuclear localiza-
tion of these two molecules could signiﬁcantly contribute in
increasing the transcription of genes under estrogen control and
tumorigenesis in breast but not in ovary and uterus.
Although we did not observe signiﬁcant differences with re-
spect to the molecules that directly inﬂuence estrogen action,
growth factor signaling molecules through which estrogen could
indirectly increase growth and tumorigenesis are at far exceeding
levels in breast but are low or totally absent in other reproductive
tissues. Three major growth factors, IGF-1, EGF and EGFL6, that re-
quire estrogen for activation and increase cell proliferation through
several mechanisms and contribute to tumorigenesis were at far
exceeding levels in breast but were absent or at diminished levels
in other tissues (Supplementary Tables 1 and 2). In addition, two
tyrosine kinases, EGFR and MET, known tumor promoters were
also constitutively at elevated levels in breast. Unexpectedly,
GHR that increases IGF production and involved in breast develop-
ment was expressed in large amounts in breast tissue but absent in
ovary and uterus (Fig. 1). Two IGF binding proteins, IGFBP4 and
IGFBP5, which limit the availability of proliferation promoting
IGF-1, were at far diminished levels in breast. Three TGFb binding
proteins, LTBP1, LTBP3, and LTBP5, which limit the availability of
differentiation promoting, tumor suppressing TGFb were also at
far diminished levels in breast cells. Our results also show thatangiogenesis promoting growth factors, VEGF-B, VEGF-D, ECGF-1,
FGF-1 and FGF-2, were abundantly expressed in breast compared
to other tissues. To complement the growth factor mediated sig-
naling, breast tissue was also rich with molecules that function
in signal transmission (CRK, VAV3), nucleic acid synthesis (UMP-
CMPK), transcription (HIPK2) and translation (MKNK2). The above
observations demonstrated that breast tissue is very rich with
growth factors or other related molecules that increase cell prolif-
eration through several mechanisms and contribute to tumorigen-
esis. Other reproductive tissues have diminished levels of these
molecules. Our observations also suggested that growth factor sig-
naling could play a major role in predisposing the breast tissue for
tumor growths. Analyses of the micro-array data on all the differ-
entially expressed genes in breast tissue using Pathway Studio pro-
gram provide support for the role of growth factors in tumor
growths in this tissue. Pathways generated showed intricate con-
nections between the differentially expressed genes (shown in
Fig. 3) and growth factors that increase cell proliferation through
several inter-connected mechanisms could, in part, contribute to
susceptibility of breast tissue to tumorigenesis. Estrogen carcino-
genesis in breast tissue could be predominantly through growth
factors. Other reproductive tissues could be less prone to tumor
growths because of diminished growth factor signaling.
The results presented here also show that in addition to rich
proliferation promoting environment, breast tissues have poorly
expressed negative inhibitory/tumor suppressing molecules. They
include differentiation promoting, proliferation inhibiting growth
factors (FGF-9, EBAF, PSIPI, CTGF, PDGFC and PDGFRA) and proto-
oncogenes (JUN-D, MAFF-1 and FOSB-1). Other poorly expressed
negative signaling molecules include tumor suppressors (LTSCR2,
TUSC3, WT1, and TSC22) and apoptosis promoters (CASP9, CSEIL,
I. Poola et al. / FEBS Letters 583 (2009) 3069–3075 3075DPF2). While we have screened for major signaling molecules here,
it is possible that there may be other molecules that could contrib-
ute to tumorigenesis in breast.
In summary, our results show for the ﬁrst time that breast
molecular constitution is signiﬁcantly different from other repro-
ductive tissues with respect to the balance in positive growth
and negative inhibitory signaling molecules. Overall, breast tissues
have abundant expressions of genes that promote cell prolifera-
tion, survival, and angiogenesis and signiﬁcantly diminished levels
of negative signaling molecules that inhibit proliferation and pro-
mote apoptosis, differentiation, and tumor suppression in compar-
ison with other reproductive tissues. Breast tissue molecular
constitution may, in part, contribute in supporting tumor growths
and other reproductive tissues are less vulnerable because of low
expression of growth factors and other molecules through which
estrogen could promote tumorigenesis. The molecular information
presented above will form a foundation for understanding differ-
ential effects of endogenous as well as exogenous factors on differ-
ent tissues.
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